Literature DB >> 8002082

Increased levels of tumor necrosis factor alpha (TNF-alpha) and interleukin 1 beta (IL-1 beta) in tracheal aspirates of newborns with pneumonia.

C Buck1, H Gallati, F Pohlandt, P Bartmann.   

Abstract

Pneumonia is one of the major sites of infection in ventilated newborns. We investigated whether the cytokines IL-1 beta and TNF-alpha are detectable in tracheal aspirates of newborns with pneumonia as a diagnostic marker. All 12 infants with pneumonia had elevated levels of IL-1 beta (range 30-300 pg/ml) and TNF-alpha (range 60-680 pg/ml), whereas control infants (n = 21; respiratory distress syndrome, very low birth weight or infants intubated preoperatively) had no detectable levels of IL-1 beta or TNF-alpha. In vitro investigations with mononuclear cells of umbilical cord blood were performed to rule out that exogenously added surfactant influences IL-1 beta and TNF-alpha production. It is concluded that IL-1 beta and TNF-alpha are important and specific mediators of neonatal pneumonia which may be of diagnostic importance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8002082     DOI: 10.1007/BF01739905

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  Tumour necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome.

Authors:  A B Millar; N M Foley; M Singer; N M Johnson; A Meager; G A Rook
Journal:  Lancet       Date:  1989-09-23       Impact factor: 79.321

2.  High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis.

Authors:  P M Suter; S Suter; E Girardin; P Roux-Lombard; G E Grau; J M Dayer
Journal:  Am Rev Respir Dis       Date:  1992-05

3.  The intratracheal administration of endotoxin and cytokines. I. Characterization of LPS-induced IL-1 and TNF mRNA expression and the LPS-, IL-1-, and TNF-induced inflammatory infiltrate.

Authors:  T R Ulich; L R Watson; S M Yin; K Z Guo; P Wang; H Thang; J del Castillo
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

4.  [Pneumonias in newborn infants and young infants].

Authors:  R Roos
Journal:  Monatsschr Kinderheilkd       Date:  1993-05       Impact factor: 0.323

5.  Increased levels of bronchoalveolar lavage fluid interleukin-6 in preterm ventilated infants after prolonged rupture of membranes.

Authors:  J M Grigg; A Barber; M Silverman
Journal:  Am Rev Respir Dis       Date:  1992-04

6.  Increased levels of interleukin-1 in bronchoalveolar washings from children with bacterial pulmonary infections.

Authors:  R W Wilmott; J T Kassab; P L Kilian; W R Benjamin; S D Douglas; R E Wood
Journal:  Am Rev Respir Dis       Date:  1990-08

7.  Phagocytic functions and tumor necrosis factor secretion of human monocytes exposed to natural porcine surfactant (Curosurf).

Authors:  C P Speer; B Götze; T Curstedt; B Robertson
Journal:  Pediatr Res       Date:  1991-07       Impact factor: 3.756

8.  Release of interleukin-1 by alveolar macrophages of patients with active pulmonary sarcoidosis.

Authors:  G W Hunninghake
Journal:  Am Rev Respir Dis       Date:  1984-04

9.  Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease.

Authors:  P Groneck; D Reuss; B Götze-Speer; C P Speer
Journal:  J Pediatr       Date:  1993-06       Impact factor: 4.406

10.  Normal human alveolar macrophages obtained by bronchoalveolar lavage have a limited capacity to release interleukin-1.

Authors:  M D Wewers; S I Rennard; A J Hance; P B Bitterman; R G Crystal
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

  10 in total
  1 in total

Review 1.  Diagnostic tests for bacterial infection from birth to 90 days--a systematic review.

Authors:  P W Fowlie; B Schmidt
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-03       Impact factor: 5.747

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.